Pressurised intraperitoneal aerosolised chemotherapy in the management of cancer of the colon, ovary and stomach: phase II randomised controlled trial of efficacy in peritoneal metastases

Ajakaiye, Anu, Brogden, Elena, Murphy, Jamie, Peters, Christopher, Frost, Jonathan, Adams, Richard ORCID: https://orcid.org/0000-0003-3915-7243, Hudson, Emma, Perry, Kitrick, Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052, Hamilton, Rebecca, Nixon, Lisette ORCID: https://orcid.org/0000-0002-1270-6970, Arndell, Karen, Gwynne, Sarah, Torkington, Jared and Jones, Sadie 2024. Pressurised intraperitoneal aerosolised chemotherapy in the management of cancer of the colon, ovary and stomach: phase II randomised controlled trial of efficacy in peritoneal metastases. Presented at: International Society of Gynecologic Cancer 2024 Annual Global Meeting, Dublin, Ireland, 16-18 October 2024. International Journal of Gynecological Cancer. , vol.34 BMJ Publishing Group, A350-A351. 10.1136/ijgc-2024-IGCS.611

Preview

PDF - Accepted Post-Print Version Download (377kB) | Preview

Abstract

Introduction: Up to 13%, 50% and 14% of patients with bowel, ovarian and stomach cancer respectively, present with peritoneal metastases (PM) which is difficult to treat with conventional chemotherapy. Pressurised IntraPeritoneal Aerosol Chemotherapy (PIPAC) which delivers chemotherapy into the peritoneal cavity, directly to the tumour site, as an aerosol during keyhole surgery is emerging as a potential new strategy. This trial aims to determine if PIPAC given with (colorectal, stomach) or instead of (ovarian) systemic anti-cancer therapy (SACT) improves Peritoneal Progression Free Survival (pPFS) compared to standard SACT. Methods: PICCOS trial (PIPAC In Cancers of the Colon, Ovaries and Stomach) is a multi-arm, prospective randomised controlled trial (RCT) in the UK designed to provide high quality evidence regarding the efficacy of PIPAC in improving pPFS. Each cancer type will have individual eligibility criteria and protocols to allow for the necessary variations in treatment. In all cancer types, patients will be randomised in a 1:1 ratio to receive either standard SACT or a combination of standard SACT and/or PIPAC, where three PIPAC procedures are performed. We aim to recruit 78 colorectal, 66 ovarian and 72 stomach cancer patients over 2.5 years and follow-up will last for a minimum of 6 months. Current Trial Status: This is the largest RCT in the world that is investigating the efficacy and impact on quality of life of PIPAC in the treatment of PM. PICCOS aims to provide high quality evidence to guide clinical practice and further research. The trial is currently recruiting.

Item Type:	Conference or Workshop Item (Poster)
Date Type:	Published Online
Status:	Published
Schools:	Medicine Centre for Trials Research (CNTRR)
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RD Surgery R Medicine > RG Gynecology and obstetrics
Publisher:	BMJ Publishing Group
ISSN:	1048-891X
Funders:	NIHR
Date of First Compliant Deposit:	30 January 2025
Date of Acceptance:	18 July 2024
Last Modified:	06 Feb 2025 10:15
URI:	https://orca.cardiff.ac.uk/id/eprint/173388

Actions (repository staff only)

Edit Item